Clinical Trial Update: Efficacy Study of Canakinumab to Treat Urticaria [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating canakinumab for chronic idiopathic urticaria; the current status of the study is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Urticaria

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: University of Zurich | Conditions: Chronic Idiopathic Urticaria | Phase 2 | Status: UNKNOWN